表紙
市場調查報告書
商品編碼
871430

思覺失調症治療藥市場 - 成長,趨勢,及預測(2019年-2024年)

Schizophrenia Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 121 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球思覺失調症治療藥市場的相關調查,市場概況和成長要素、阻礙因素,各治療等級、治療方法、地區的市場分析,競爭情形,主要企業的簡介等資訊彙整。

目錄

第1章 簡介

  • 研究成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 思覺失調症及相關疾病的盛行率上升
    • 對精神衛生的政府及醫療機關的焦點擴大
    • 對研究開發的投資擴大
  • 市場阻礙因素
    • 藥物相關中毒病例的增加
    • 主要醫藥品的專利失效
  • 波特五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業的競爭

第5章 市場區隔

  • 各治療等級
    • 第二代抗精神病藥
    • 第三代抗精神病藥
    • 其他
  • 各治療法
    • 口服
    • 注射劑
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東及非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Alkermes plc
    • Allergan plc
    • AstraZeneca
    • Bristol-Myers Squibb
    • Eli Lilly and Company
    • Johnson & Johnson
    • Pfizer, Inc
    • 大日本住友製藥株式會社
    • Vanda Pharmaceuticals

第7章 市場機會及今後趨勢

目錄
Product Code: 64928

The schizophrenia drugs market is expected to register a CAGR of nearly 3.24% during the forecast period, with a revenue of approximately USD 7.8 billion in 2020, and it is expected to reach USD 9.3 billion by 2026.

The COVID-19 pandemic has been continuing to transform the growth of various markets, the immediate impact of the outbreak is varied. While a few industries registered a drop in demand, numerous other markets may continue to remain unscathed and show promising growth opportunities. Initially, the outbreak of COVID-19 worldwide and the lockdown situation across some countries have shown some challenges on the market studied, due to hold on services by the hospitals and clinics, in order to prevent the spread of the COVID-19 virus. The COVID-19 pandemic has a profound effect on mental health. In addition, schizophrenia condition directly increases the risk of contracting COVID-19. However, the underlying health conditions in people with schizophrenia can contribute to more serious COVID-19 symptoms. According to the study article "COVID-19 paranoia in a patient suffering from schizophrenic psychosis" published in June 2020, the COVID-19 pandemic has triggered coronavirus-related hallucinations and delusions, along with changes in the mood in patient population.

Moreover, Subtle changes in cognition and social relationships are expected to precede the actual diagnosis, often by years. According to the World Health Organization 2019 report, the disease affects 20 million people worldwide. Furthermore, this number is likely to continue to increase, along with the growth in the aging population. According to the World Ageing 2019 report, in 2019, there were around 703 million population aged 65 years or over in the world. The number of older persons is projected to double to 1.5 billion in 2050. Globally, the share of the population aged 65 years or over increased from 6% in 1990 to 9% in 2019. The aging population are more susceptible to late onset schizophrenia which will further boost the overall market growth. In addition, the American Psychiatric Association and the National Institute of Mental Health had estimated that the risk of individual having schizophrenia during some point in their life to be between 0.3 and 0.7 percent.

Moreover, the increase in the number of patients taking treatment and rising demand for improved healthcare infrastructure are expected to drive the market. In recent years, the government in several countries have collaborated well with many hospitals across nations to give more protection to people from schizophrenia. The rising burden of the disease and the increasing need to manage it effectively is driving the growth of the market studied.

However, the increase in cases of addiction associated with these drugs and patent expiry of major drugs are hampering the overall market growth.

Key Market Trends

The Second-generation Antipsychotics Sub-segment is Expected to record the Better Growth Over the Forecast Period

The COVID-19 pandemic has affected the supply chain of pharmaceutical products. The restrictions on pharmaceutical manufacturing and export had affected many products sold in some countries, such as the United States, Europe, and other countries. Some of the drugs are manufactured in-house at the pharma companies, while other drugs of the company are manufactured with facilities in other countries, such as contract manufacturing services, which further impacted the supply chain of products. Hence the delayed supply of Second-generation Antipsychotics in pharmacies and other end-user settings caused by restriction or cancellation of the export of medicines have negatively impacted the market growth. However, restrictions on import and export are now being partially relieved which further creates growth avenues in the forecasted period.

Moreover, The usual first-line treatment for schizophrenia is an antipsychotic medication. One of the commonly preferred medications is risperidone, which is also known as a second-generation antipsychotic (SGA) or atypical antipsychotic. Risperidone rebalances dopamine and serotonin to improve thinking, mood, and behavior. It is expected to help in curing some or all of the symptoms of schizophrenia. Moreover, in the United States the Food and Drug Administration (FDA) approved for acute treatment of manic or mixed episodes of bipolar disorder, maintenance (long-term) treatment of bipolar disorder (Risperdal Consta only), and irritability associated with autistic disorders. There are several second-generation drugs available in the market, which are commonly proposed by doctors/physicians. Moreover second-generation and third-generation antipsychotics is considered to be the standard of care in the schizophrenia treatment. Some of the brands prescribed for the managmeent of schizophrenia are Abilify, Zyprexa, Seroquel, Aristada, Latuda, Saphris, and Vraylar among others

Furthermore, continuous support by the government to private and public healthcare companies also boosts the growth of companies in this segment. Therefore, considering the aforementioned reasons, the market for second-generation antipsychotics is likely to grow steadily over the forecast period.

The North American is Expected to Dominate the Market Over the Forecast Period

The United States is the most COVID-affected country across the world. The supply chain of products was highly impacted in this country. Initially, there is a decline in demand for schizophrenia drugs which has negatively impacted the overall market growth.

Moreover, the North American region is expected to dominate the market studied over the forecast period. In the North American region, the United States accounted for the largest market share, as a major section of the population is approaching such medications therapies, primarily due to hectic lifestyles. Moreover, the country offers highly advanced medical care, for early treatment capabilities, along with the involvement of the government in increasing healthcare expenditure. This is driving the growth of the market studied. According to the statistics provided by National Alliance on Mental Illness, 2019, the prevalence of schizophrenia among U.S adults is estimated to be around 1.5 million people per year. In addition, according to the National Institute of Mental Health, 2018) this condition is often diagnosed in the young population with common symptoms presenting earlier in males than in females. In addition in September 2020 the American Psychiatric Association (APA) announced the new evidence-based practice guideline for enhancing the treatment of patients with schizophrenia condition. The goal of American Psychiatric Association is to reduce the mortality, morbidity and significant psychosocial and health consequences associated with this psychiatric condition. Hence such government initiatives is also fueling the overall market growth in North America region. Moreover, technological advancements in the development of new drugs, increasing healthcare expenditure and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Schizophrenia Drugs market is competitive and consists of major and small players. In terms of market share, the major players currently dominate the market. Some of the major market players include Alkermes Plc, Bristol-Myers Squibb, Eli Lilly and Company, Johnson & Johnson, and Allergan Plc, among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Schizophrenia and Associated Disorders
    • 4.2.2 Increase in Focus of Governments and Health Care Organizations on Mental Health
    • 4.2.3 Increasing Investments in R&D
  • 4.3 Market Restraints
    • 4.3.1 Increase in Cases of Addiction Associated with these Drugs
    • 4.3.2 Patent Expiry of Major Drugs
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Therapeutic Class
    • 5.1.1 Second-generation Antipsychotics
    • 5.1.2 Third-generation Antipsychotics
    • 5.1.3 Other Therapeutic Classes
  • 5.2 By Treatment
    • 5.2.1 Oral
    • 5.2.2 Injectables
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Alkermes Plc
    • 6.1.2 Abbvie (Allergan Plc)
    • 6.1.3 AstraZeneca
    • 6.1.4 Eli Lilly and Company
    • 6.1.5 Johnson & Johnson
    • 6.1.6 Pfizer Inc.
    • 6.1.7 Sumitomo Dainippon Pharma
    • 6.1.8 Vanda Pharmaceuticals
    • 6.1.9 Bristol-Myers Squibb and Company
    • 6.1.10 Otsuka America Pharmaceutical, Inc.
    • 6.1.11 Acadia Pharmaceuticals
    • 6.1.12 Karuna Therapeutics

7 MARKET OPPORTUNITIES AND FUTURE TRENDS